CRISPR Therapeutics AG (CRSP) P/E Ratio History
Deep ValueTrading at -8.4x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2019–2022
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, CRISPR Therapeutics AG (CRSP) trades at a price-to-earnings ratio of -8.4x, with a stock price of $54.09 and trailing twelve-month earnings per share of $-5.92.
The current P/E is 116% below its 5-year average of 52.7x. Over the past five years, CRSP's P/E has ranged from a low of 17.1x to a high of 159.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CRSP trades at a 138% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, CRSP trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CRSP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CRSP Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CRSP P/E vs Peers
RNA and Genome Editing Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $115B | 29.5 | 3.56 | +837%Best | |
| $63B | 14.7Lowest | 2.32Best | +8% | |
| $25B | 29.7 | 7.02 | +171% | |
| $173B | 26.2 | 12.40 | +7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CRSP Historical P/E Data (2019–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q1 | - | $62.77 | $3.61 | 17.4x | -67% |
| FY2021 Q4 | Dec 31 2021 | $75.78 | $4.42 | 17.1x | -67% |
| FY2021 Q3 | - | $111.93 | $4.73 | 23.7x | -55% |
| FY2021 Q2 | Jun 30 2021 | $161.89 | $5.08 | 31.9x | -40% |
| FY2020 Q2 | - | $73.49 | $0.46 | 159.8x | +203% |
| FY2020 Q1 | - | $42.41 | $0.75 | 56.5x | +7% |
| FY2019 Q4 | - | $60.91 | $0.97 | 62.8x | +19% |
Average P/E for displayed period: 52.7x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CRSP — Frequently Asked Questions
Quick answers to the most common questions about buying CRSP stock.
What is CRSP's P/E ratio?
CRISPR Therapeutics AG (CRSP) trailing twelve-month P/E ratio is -8.4x, based on TTM diluted EPS of $-5.92. The 5-year average P/E is 52.7x and the historical range spans 17.1x to 159.8x.
Is CRSP stock overvalued or undervalued?
CRSP trades at -8.4x P/E, below its 5-year average of 52.7x. At the 0th percentile of its historical range (17.1x–159.8x), the stock is priced at a discount to its own history.
Is CRSP stock expensive?
No, CRSP is not expensive on a historical basis. The current P/E of -8.4x is below the 5-year average of 52.7x and sits at the 0th percentile of its valuation range.
What is CRSP's historical P/E range?
Over the past 5 years, CRSP's P/E ratio has ranged from 17.1x to 159.8x, with a median of 31.9x and an average of 52.7x. The current P/E of -8.4x places the stock at the 0th percentile of this range. Full historical data spans 2019–2022.
How does CRSP's P/E compare to the S&P 500?
CRSP trades at -8.4x P/E versus the S&P 500 median of 24.4x. The 134% discount to the market suggests lower growth expectations or perceived higher risk.
How does CRSP's valuation compare to Healthcare peers?
CRISPR Therapeutics AG P/E of -8.4x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CRSP's PEG ratio?
CRSP PEG ratio is N/A, based on a P/E of -8.4x and EPS growth of -49.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CRSP's earnings yield?
CRSP earnings yield is N/A, the inverse of its -8.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.